Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
376.87 M CHF
2.23 B CHF
342.12 M
About NOVONESIS (NOVOZYMES A/S) B
Sector
CEO
Ester Baiget
Headquarters
Lyngby
Website
ISIN
DK0060336014
FIGI
BBG006TLSNH9
Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NZYMB is 44.68 CHF — it hasn't changed in the past 24 hours. Watch NOVOZYMES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange NOVOZYMES stocks are traded under the ticker NZYMB.
We've gathered analysts' opinions on NOVOZYMES future price: according to them, NZYMB price has a max estimate of 73.59 CHF and a min estimate of 45.71 CHF. Watch NZYMB chart and read a more detailed NOVOZYMES stock forecast: see what analysts think of NOVOZYMES and suggest that you do with its stocks.
NZYMB reached its all-time high on Jan 5, 2018 with the price of 55.98 CHF, and its all-time low was 32.75 CHF and was reached on Dec 8, 2016. View more price dynamics on NZYMB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NZYMB stock is 0.00% volatile and has beta coefficient of 0.33. Track NOVOZYMES stock price on the chart and check out the list of the most volatile stocks — is NOVOZYMES there?
Today NOVOZYMES has the market capitalization of 23.89 B, it has decreased by −4.27% over the last week.
Yes, you can track NOVOZYMES financials in yearly and quarterly reports right on TradingView.
NOVOZYMES is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
NZYMB earnings for the last quarter are 0.34 CHF per share, whereas the estimation was 0.48 CHF resulting in a −30.34% surprise. The estimated earnings for the next quarter are 0.62 CHF per share. See more details about NOVOZYMES earnings.
NOVOZYMES revenue for the last quarter amounts to 962.78 M CHF, despite the estimated figure of 949.64 M CHF. In the next quarter, revenue is expected to reach 931.51 M CHF.
NOVOZYMES dividend yield was 1.67% in 2023, and payout ratio reached 56.80%. The year before the numbers were 1.71% and 45.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 15, 2024, the company has 6.76 K employees. See our rating of the largest employees — is NOVOZYMES on this list?
Like other stocks, NZYMB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVOZYMES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVOZYMES technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVOZYMES stock shows the sell signal. See more of NOVOZYMES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.